A study on GLP1RA medications found that behavioral side effects likely do not result from direct action on GLP1R.
Eli Lilly (NYSE: LLY) stock was the picture of health on Friday. Shares of the massive American pharmaceutical company rose ...
Finally, some good news for Novo Nordisk (NYSE: NVO) shareholders! Twice in the past two months, the Danish manufacturer of ...
The readout comes on the heels of CagriSema’s disappointing Phase III performance, where it missed Novo’s projection of 25% ...
Maintaining a healthy weight is good for your body and can also help with self-esteem. If you’ve been trying to lose weight, ...
11h
Ozempic and Wegovy do the same thing as GLP-1 would normally do for you — but to enable them to treat diabetes and obesity, ...
Topline data were announced from a phase 3b trial evaluating investigational semaglutide 7.2mg in adults with obesity.
A Medscape survey found that a strong majority of physicians believe high-risk patients should have easier access to new weight loss drugs.
Dr. George Carroll runs BeSlimMD, a private weight loss clinic in Maitland. He has been helping patients lose weight for more than 40 years, but says when so called GLP-1 drugs made from semaglutide ...
A major new study has revealed a long list of benefits and some little-known risks of Ozempic and other GLP-1 medications.
THESE MEDICATIONS ARE MOSTLY KNOWN FOR TREATING DIABETES AND OBESITY.. BUT THE F-D-A HAS APPROVED THEM FOR PREVENTING HEART DISEASE AFTER STUDIES LAST FALL. THAT SHOWED ABOUT A 20% REDUCTION IN ...
Semaglutide, sold under the brand names of Ozempic, Rybelsus and Wegovy, is one of the most popular drugs on the market.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback